Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels to Predict Exercise Capacity in Hypertrophic Cardiomyopathy

American Journal of Cardiology

Volumn 98, Issue 4, 2006, Pages 515-519

  Thaman, Rajesh ^a   Esteban, Maite Tome ^a   Barnes, Sophie ^b   Gimeno, Juan R ^a   Mist, Bryan ^a   Murphy, Ross ^a   Collinson, Paul O ^b   McKenna, William J ^a   Elliott, Perry M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DOPPLER ECHOGRAPHY; FEMALE; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MULTIVARIATE ANALYSIS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 33746662852     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.02.057     Document Type: Article

References (30)

1. De Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 26 (2003) 316-322
2. Gardner R.S., Ozalp F., Murday A.J., Robb S.D., and McDonagh T.A. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
3. Wu A.H., Smith A., Wieczorek S., Mather J.F., Duncan B., White C.M., McGill C., Katten D., and Heller G. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 (2003) 628-631
4. Cowie M.R., and Mendez G.F. BNP and congestive heart failure. Curr Probl Cardiol 28 (2003) 264-311
5. Lainchbury J.G., Campbell E., Frampton C.M., Yandle T.G., Nicholls M.G., and Richards A.M. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
6. Maewal P., and De Lemos J.A. Natriuretic peptide hormone measurement in acute coronary syndromes. Heart Fail Rev 8 (2003) 365-368
7. Morrow D.A., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L.A., DiBattiste P.M., McCabe C.H., Gibson C.M., Cannon C.P., and Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
8. Silvet H., Young-Xu Y., Walleigh D., and Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92 (2003) 1124-1127
9. Rossi A., Enriquez-Sarano M., Burnett Jr. J.C., Lerman A., Abel M.D., and Seward J.B. Natriuretic peptide levels in atrial fibrillation. a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 35 (2000) 1256-1262
10. Gerber I.L., Stewart R.A., Legget M.E., West T.M., French R.L., Sutton T.M., Yandle T.G., French J.K., Richards A.M., and White H.D. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
11. Qi W., Mathisen P., Kjekshus J., Simonsen S., Bjornerheim R., Endresen K., and Hall C. Natriuretic peptides in patients with aortic stenosis. Am Heart J 142 (2001) 725-732
12. Weber M.W., Rau M., Maikowski C., Keil E., Mitrovic V., Maksimovic R., Brandt R.R., and Hamm C. N-terminal pro-BNP as a biochemical marker for assessing severity of aortic stenosis. J Am Coll Cardiol 41 suppl (2003) 508-509
13. Suzuki M., Hamada M., Yamamoto K., Kazatani Y., and Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 25 (2002) 669-676
14. Almeida S.S., Azevedo A., Castro A., Frioes F., Freitas J., Ferreira A., and Bettencourt P. B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology 98 (2002) 113-115
15. Kinugawa T., Kato M., Ogino K., Igawa O., Hisatome I., Shigemasa C., and Nohara R. Neurohormonal determinants of peak oxygen uptake in patients with chronic heart failure. Jpn Heart J 44 (2003) 725-734
16. Jourdain P., Funck F., Bellorini M., Guillard N., Loiret J., Thebault B., Desnos M., and Duboc D. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 5 (2003) 155-160
17. Kruger S., Graf J., Kunz D., Stickel T., Hanrath P., and Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 40 (2002) 718-722
18. Isnard R., Pousset F., Chafirovskaia O., Carayon A., Hulot J.S., Thomas D., and Komajda M. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 146 (2003) 729-735
19. Mizuno Y., Yoshimura M., Harada E., Nakayama M., Sakamoto T., Shimasaki Y., Ogawa H., Kugiyama K., Saito Y., Nakao K., and Yasue H. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 86 (2000) 1036-1040
20. Hasegawa K., Fujiwara H., Doyama K., Miyamae M., Fujiwara T., Suga S., Mukoyama M., Nakao K., Imura H., and Sasayama S. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88 (1993) 372-380
21. Briguori C., Betocchi S., Manganelli F., Gigante B., Losi M.A., Ciampi Q., Gottilla R., Violante A., Tocchetti C.G., Volpe M., and Chiariello M. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J 22 (2001) 1328-1336
22. Maron B.J., Tholakanahalli V.N., Zenovich A.G., Casey S.A., Duprez D., Aeppli D.M., and Cohn J.N. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109 (2004) 984-989
23. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93 (1996) 841-842
24. McKenna W.J., Spirito P., Desnos M., Dubourg O., and Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy. proposal for new diagnostic criteria in adult members of affected families. Heart 77 (1997) 130-132
25. Shapiro L.M., and McKenna W.J. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. a two-dimensional echocardiographic study. J Am Coll Cardiol 2 (1983) 437-444
26. Nihoyannopoulos P., Karatasakis G., Frenneaux M., McKenna W.J., and Oakley C.M. Diastolic function in hypertrophic cardiomyopathy. relation to exercise capacity. J Am Coll Cardiol 19 (1992) 536-540
27. Briguori C., Betocchi S., Romano M., Manganelli F., Angela Losi M., Ciampi Q., Gottilla R., Lombardi R., Condorelli M., and Chiariello M. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. Am J Cardiol 84 (1999) 309-315
28. Lele S.S., Thomson H.L., Seo H., Belenkie I., McKenna W.J., and Frenneaux M.P. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation 92 (1995) 2886-2894
29. Hirata Y., Matsumoto A., Aoyagi T., Yamaoki K., Komuro I., Suzuki T., Ashida T., Sugiyama T., Hada Y., Kuwajima I., et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 51 (2001) 585-591
30. Bay M., Kirk V., Parner J., Hassager C., Nielsen H., Krogsgaard K., Trawinski J., Boesgaard S., and Aldershvile J. NT-proBNP. a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 89 (2003) 150-154